Page 185 - 2019_01-Haematologica-web

Prognostic markers in autoimmune TTP
episodes in patients with thrombotic thrombocytopenic purpura: The experi- ence from the Ohio State University Registry. Am J Hematol. 2018;93(3):E73- E75.
30. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of termi- nology in thrombotic thrombocytopenic purpura and related thrombotic microan- giopathies. J Thromb Haemost. 2016;15(2):312-322.
31. Grillberger R, Casina VC, Turecek PL, Zheng XL, Rottensteiner H, Scheiflinger F. Anti-ADAMTS13 IgG autoantibodies pres- ent in healthy individuals share linear epi- topes with those in patients with throm-
botic thrombocytopenic purpura.
Haematologica. 2014;99(4):e58-60.
32. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secret- ed ultralarge von Willebrand factor multi- mers on the endothelial surface under flow- ing conditions. Blood. 2002;100(12):4033-
4039.
33. Moake JL, Rudy CK, Troll JH, et al.
Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432- 1435.
34. Sadler JE. A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci USA.
2002;99(18):11552-11554.
35. Jin SY, Xiao J, Bao J, Zhou S, Wright JF,
Zheng XL. AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin- induced thrombotic thrombocytopenic purpura. Blood. 2013;121(19):3825-3829, S1-3.
36. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8(11):622-633.
37. Patton JF, Manning KR, Case D, Owen J. Serum lactate dehydrogenase and platelet count predict survival in thrombotic throm- bocytopenic purpura. Am J Hematol. 1994; 47(2):94-99.
haematologica | 2019; 104(1)
175